Skip to main content
Premium Trial:

Request an Annual Quote

Jay Flatley

Juno Therapeutics has appointed Jay Flatley to its board of directors. He currently serves as executive chairman of Illumina and as the chair for the board of directors of Illumina's subsidiary, Helix. He also serves an advisory board member for UC San Diego's Moore Cancer Center, serves as the board of directors at Coherent and Denali, and is on the board of trustees of the Salk Institute. Previously, he served as CEO of Illumina from 1999 to 2016.  Before Illumina, he served as president and CEO of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.